China NT Pharma Group Co (HKSE:01011) ROCE %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01011 China NT Pharma Group Co Ltd HKSE:01011
1 GF Score
Price HK$0.42
! 4 Warning Signs
View Full Analysis

What is China NT Pharma Group Co ROCE %?

China NT Pharma Group Co HKSE:01011 -6.67% 1 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:01011 with a GF Score™ of 1/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China NT Pharma Group Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.


China NT Pharma Group Co  (HKSE:01011) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


China NT Pharma Group Co ROCE % Related Terms


China NT Pharma Group Co ROCE % Historical Data

* Premium members only.

The historical data trend for China NT Pharma Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China NT Pharma Group Co ROCE % Chart

China NT Pharma Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.01 0.00 0.00 0.00 0.00

China NT Pharma Group Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:01011
1GF Score
China NT Pharma Group Co Ltd HKSE:01011
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China NT Pharma Group Co ROCE % Calculation

China NT Pharma Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1.751/( ( (356.683 - 774.132) + (383.724 - 686.14) )/ 2 )
=1.751/( (-417.449+-302.416)/ 2 )
=1.751/-359.9325
=-0.49 %

China NT Pharma Group Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=8.604/( ( (376.46 - 678.693) + (383.724 - 686.14) )/ 2 )
=8.604/( ( -302.233 + -302.416 )/ 2 )
=8.604/-302.3245
=0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
China NT Pharma Group Co (HKSE:01011) has a ROCE % of 0.00% as of Dec. 2025.
Is China NT Pharma Group Co's ROCE % too high?
China NT Pharma Group Co's current ROCE % is 0.00%. Overall, China NT Pharma Group Co has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does China NT Pharma Group Co's ROCE % compare to ZTS?
China NT Pharma Group Co's ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.63, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China NT Pharma Group Co's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China NT Pharma Group Co stock overvalued right now?
China NT Pharma Group Co (HKSE:01011) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. China NT Pharma Group Co's overall GF Score™ is 1/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For China NT Pharma Group Co (HKSE:01011), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

China NT Pharma Group Co Business Description

Address 168-200 Connaught Road, Unit 2102, 21st Floor, West Tower, Shun Tak Centre, Central, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The Group's operations are regarded as having two operating and reportable segments, namely Agency Services and Healthcare Related Services. The company generates maximum of its revenue from Healthcare Related Services.
1GF Score

Get the complete analysis for HKSE:01011

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.42
Price